Doxazosin
Cardura (doxazosin) is a small molecule pharmaceutical. Doxazosin was first approved as Cardura on 1990-11-02. It is used to treat hypertension, prostatic hyperplasia, and urinary retention in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Cardura (generic drugs available since 2000-10-18)
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
cardura | New Drug Application | 2022-02-14 |
doxazosin mesylate | ANDA | 2023-06-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hypertension | EFO_0000537 | D006973 | I10 |
prostatic hyperplasia | EFO_0000284 | D011470 | N40 |
urinary retention | HP_0000016 | D016055 | R33 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Apnea | D001049 | HP_0002104 | R06.81 | — | — | 1 | 1 | — | 2 |
Hypoxia | D000860 | R09.02 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anesthesia | D000758 | — | 1 | — | — | 1 | 2 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | DOXAZOSIN |
INN | doxazosin |
Description | Doxazosin is a member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure. It has a role as an antihypertensive agent, an alpha-adrenergic antagonist, an antineoplastic agent, a vasodilator agent and an antihyperplasia drug. It is a member of quinazolines, a N-acylpiperazine, a N-arylpiperazine, a benzodioxine, a monocarboxylic acid amide and an aromatic amine. |
Classification | Small molecule |
Drug class | antihypertensives (prazosin type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC |
Identifiers
PDB | — |
CAS-ID | 74191-85-8 |
RxCUI | — |
ChEMBL ID | CHEMBL707 |
ChEBI ID | 4708 |
PubChem CID | 3157 |
DrugBank | DB00590 |
UNII ID | NW1291F1W8 (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA1A
ADRA1A
ADRA1B
ADRA1B
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1A
Gene synonyms
ADRA1C
NCBI Gene ID
Protein name
alpha-1A adrenergic receptor
Protein synonyms
Alpha-1A adrenoceptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c, G protein coupled receptor
Uniprot ID
Mouse ortholog
Adra1a (11549)
alpha-1A adrenergic receptor (Q8BV77)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Cardura - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,711 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
33 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more